709 / 1082
S693
ESTRO 36 2017
_______________________________________________________________________________________________
(11p in progression status and 191p with no evidence of
disease). Anemia monitoring: only 36p (53.7%) of 67p with
anemia detected before RDT, underwent subsequent Hb
control (during or after RDT). Only 27p of 67p with anemia
were previously treated with chemotherapy (40p were
anemic with no systemic treatment). Differences between
mean Hb levels were statistically significant for Hb1-Hb2
(p=,00), Hb1-Hb4 (p=,005), Hb3-Hb4 (p=,004) and Hb2-Hb4
(p=,001).
Patients with pre-treatment Hb level <12g/dL presented
worse overall survival (p=.021, Chi2 5.3), with mean OS of
53.39 months (range 45.5-61.3) vs. 61.4 (range 58.4-64.4)
in patients with ≥ 12g/dL.
Conclusion
Despite evidence that anemia is frequent in patients with
endometrial carcinoma and determine OS, the follow-up
of anemia in cancer patients is still suboptimal. There is a
strong need of guidelines for anemia monitoring in cancer
patients.
EP-1306 New pre-treatment eosinophiles-related
ratios as predictive factors for OS in endometrial
carcinoma.
K. Holub
1
, A. Biete
1
1
Hospital Clínic i Universitari de Barcelona, Radiation
Oncology Dpt., Barcelona, Spain
Purpose or Objective
To analyze the influence eosinophil levels in prognosis of
endometrial carcinoma.
Material and Methods
We retrospectively evaluated 233 patients (p) out of a
total cohort of 248p diagnosed with endometrial
carcinoma and treated with radiotherapy (RDT) in our
center between January 2011 and December 2015. We
analyzed the prognostic value of pretreatment
eosinophiles as well as we described new eosinophils-
related ratios in endometrial cancer: Eosinophil-to-
Lymphocyte Ratio and Eosinophil*Neutrophile-to-
Lymphocyte Ratio. Statistics: Chi-square, Kaplan-Meier
method.
Results
Age at diagnosis (years): mean 64.9 (range 36-90). All
patients underwent surgery before RDT, with pelvic
lymphadenectomy in 187p (80.3%). Histology:
Endometrioid 172p (73.8%), non-endometrioid 61p
(26.2%). FIGO stage (2009): IA-60p (27.8%), IB-92p (39.5%),
II-32p (13.7%), IIIA-9p (3.9%), IIIB-0, IIIC1-20 (8.6%), IIIC2-
8 (3.4%), IVA-9 (3.9%), IVB-3(1.3%). Grade: I-50p (21.5%),
II-91p (39%), III-88p (37.8%). External beam radiotherapy
(EBRT) dose (Gy): mean 44.2 (range 9-65). Brachytherapy
(BT) dose (Gy): mean 10.2 (range 5-20). Majority of
patients was treated with combination of EBRT and BT.
EBRT+BT dose (Gy): mean 41.2 (range 5-75). Mean follow-
up (months): mean 32 (SD 17.5). Progression was observed
in 40p (17.2%): only one patient developed pelvic node
recurrence, 39p developed distant recurrence (4p with
simultaneous vaginal progression, 3p with regional
progression and one 1p with both vaginal and regional
progression, remaining 31p presented exclusively distant
progression). Mortality: 31p (13.3%), including cancer-
specific mortality: 28p (12%) and 3 deaths not related with
endometrial cancer (1.3%). Remaining 202p were alive
(11p in progression status and 191p with no evidence of
disease).
Eosinophiles-
related ratios in
pre-treatment
analysis
Numb
er of
patie
nts
Mean
(rang
e)
Cu
t-
Off
Numb
er of
event
s
(deat
hs)
Overal
l
surviv
al
(mont
hs)
p
(Chi
2)
Eosinophils-to-
Lymphocytes Ratio
(ELR)
131
0.08
(0.0-
0.31)
<0.
1
vs
3 vs 9
64.0
vs
52.0
,001
(12.0
1)
≥0.
1
Eosinophiles*Neutr
ophils-to-
Lymphocytes Ratio
(ENR)
112
4.6
(1.14
-
12.5)
<0.
4
vs
≥0.
4
4 vs 8
63.0
vs
53.6
,015
(5.86
)
Conclusion
Tumor-generated inflammation is considered to be one of
the principal triggers for tumor progression. Several
hypotheses link eosinophilia with cancer, however until
now there has not been any evidence of impact of
eosinophil levels in combination with other immune cells
on prognosis of cancer. To our best knowledge, this is the
first publication describing and analyzing the eosinophil-
related ratios as a predictive factor in cancer
.
EP-1307 New neutrophils-related ratios as a novel
predictive biomarkers for endometrial carcinoma.
K. Holub
1
, A. Biete
1
1
Hospital Clínic i Universitari de Barcelona, Radiation
Oncology Dpt., Barcelona, Spain
Purpose or Objective
To analyze the influence of neutrophils, lymphocytes,
monocytes and platelet-related disorders in pre-
treatment blood analysis on prognosis of endometrial
carcinoma.
Material and Methods
We retrospectively evaluated 233 patients (p) out of a
total cohort of 248p diagnosed with endometrial
carcinoma and treated with radiotherapy (RDT) in our
center between January 2011 and December 2015. We
analyzed the prognostic value of pretreatment neutrophils
and lymphocytes levels as well as Neutrophil-to-
Lymphocyte ratio (NLR), Platelet-to-Lymphocyte ratio
(PLR), Lymphocyte-to-Monocyte ratio (LMR) and
Platelet*Neutrophil-to-Lymphocyte
ratio
(Systemic
Immune-Inflammation Index, SII) in endometrial cancer.
Statistics: Chi2, Kaplan-Meier method.
Results
Age at diagnosis (years): mean 64.9 (range 36-90). All
patients underwent surgery before RDT, with pelvic
lymphadenectomy in 187p (80.3%). Histology:
endometrioid 172p (73.8%), non-endometrioid 61p
(26.2%). FIGO stage (2009): IA-60p (27.8%), IB-92p (39.5%),
II-32p (13.7%), IIIA-9p (3.9%) ,IIIB-0, IIIC1-20 (8.6%), IIIC2-
8 (3.4%), IVA-9 (3.9%), IVB-3(1.3%). Grade: I-50p (21.5%),
II-91p (39%), III-88p (37.8%). Majority of patients was
treated with combination of EBRT and BT. EBRT+BT dose
(Gy): mean 41.2 (range 5-75), median 52. Mean follow-up
(months): mean 32 (SD 17.5). Progression was observed in
40p (17.2%): only one patient developed pelvic node
recurrence, 39p developed distant recurrence (in 4p with
simulates vaginal progression, 3p with regional
progression and one 1p with both vaginal and regional
progression, remaining 31p presented exclusively distant
progression). Mortality: 31p (13.3%), including cancer-
specific mortality: 28p (12%) and 3 deaths not related with
endometrial cancer (1.3%). The remaining 202p were alive
(11p in progression status and 191p with no evidence of
disease). Neutrophils-related ratio were calculated as
follows: NLR-absolute neutrophil count/absolute
lymphocyte count, PLR-platelet count/ absolute
lymphocyte
count,
LMR-absolute
lymphocyte
count/absolute
monocyte
count
and
SII
-
platelet*neutrophil count/lymphocyte count.
Hemogram
parameters in
pre-treatment
blood analysis
Num
ber
of
patie
nts
Mean
(range)
Cut
-Off
Numb
er of
event
s
(deat
hs)
Overa
ll
surviv
al
(mont
hs)
p
(Chi2)